Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.50+1.40 (+2.09%)
Close on Nov 17, 2026Market cap $16.71BP/E 20.5Yield –
Exelixis r&d expenses
Research and development expenses are spending on new products and technology.
Exelixis's R&D Expenses for the twelve months ending Oct 2, 2026 was $834.63M, down 3.0% year over year. For fiscal 2025 it was $825.00M, down 9.4% from the year before. Over ten years it grew 24.0% a year on average. The highest annual figure on record is $1.04B in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $825.00M | -9.4% |
| FY2024 | Jan 3, 2025 | $910.41M | -12.8% |
| FY2023 | Dec 29, 2023 | $1.04B | +17.1% |
| FY2022 | Dec 30, 2022 | $891.81M | +28.6% |
| FY2021 | Dec 31, 2021 | $693.72M | +26.6% |
| FY2020 | Jan 1, 2021 | $547.85M | +62.6% |
| FY2019 | Jan 3, 2020 | $336.96M | +84.9% |
| FY2018 | Dec 28, 2018 | $182.26M | +62.5% |
| FY2017 | Dec 29, 2017 | $112.17M | +16.9% |
| FY2016 | Dec 31, 2016 | $95.97M | -0.4% |
| FY2015 | Dec 31, 2015 | $96.35M | -49.0% |
| FY2014 | Dec 31, 2014 | $189.10M | +5.8% |
| FY2013 | Dec 31, 2013 | $178.76M | +38.7% |
| FY2012 | Dec 31, 2012 | $128.88M | -17.8% |
| FY2011 | Dec 31, 2011 | $156.84M | -25.6% |
| FY2010 | Dec 31, 2010 | $210.68M | -10.2% |
| FY2009 | Dec 31, 2009 | $234.70M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Oct 2, 2026 | $209.48M | +5.2% |
| Q2 FY2026 | Jul 3, 2026 | $211.99M | +5.8% |
| Q1 FY2026 | Apr 3, 2026 | $199.92M | -5.8% |
| Q4 FY2025 | Jan 2, 2026 | $213.25M | -14.4% |
| Q3 FY2025 | Oct 3, 2025 | $199.16M | -10.5% |
| Q2 FY2025 | Jul 4, 2025 | $200.36M | -5.1% |
| Q1 FY2025 | Apr 4, 2025 | $212.23M | -6.8% |
| Q4 FY2024 | Jan 3, 2025 | $249.00M | +1.8% |
| Q3 FY2024 | Sep 27, 2024 | $222.57M | -33.1% |
| Q2 FY2024 | Jun 28, 2024 | $211.15M | -9.2% |
| Q1 FY2024 | Mar 29, 2024 | $227.69M | -2.8% |
| Q4 FY2023 | Dec 29, 2023 | $244.67M | -27.4% |
| Q3 FY2023 | Sep 29, 2023 | $332.59M | +67.3% |
| Q2 FY2023 | Jun 30, 2023 | $232.57M | +16.6% |
| Q1 FY2023 | Mar 31, 2023 | $234.25M | +49.5% |
| Q4 FY2022 | Dec 30, 2022 | $336.82M | +51.5% |
| Q3 FY2022 | Sep 30, 2022 | $198.84M | +21.7% |
| Q2 FY2022 | Jul 1, 2022 | $199.48M | +34.1% |
| Q1 FY2022 | Apr 1, 2022 | $156.67M | -1.6% |
| Q4 FY2021 | Dec 31, 2021 | $222.27M | +44.1% |
| Q3 FY2021 | Oct 1, 2021 | $163.37M | -7.6% |
| Q2 FY2021 | Jul 2, 2021 | $148.79M | +29.5% |
| Q1 FY2021 | Apr 2, 2021 | $159.29M | +56.4% |
| Q4 FY2020 | Jan 1, 2021 | $154.28M | +63.3% |
| Q3 FY2020 | Oct 2, 2020 | $176.76M | +81.7% |
| Q2 FY2020 | Jul 3, 2020 | $114.93M | +40.3% |
| Q1 FY2020 | Apr 3, 2020 | $101.88M | +61.0% |
| Q4 FY2019 | Jan 3, 2020 | $94.45M | +64.9% |
| Q3 FY2019 | Sep 27, 2019 | $97.30M | +117.5% |
| Q2 FY2019 | Jun 28, 2019 | $81.93M | +92.8% |
| Q1 FY2019 | Mar 29, 2019 | $63.29M | +67.6% |
| Q4 FY2018 | Dec 28, 2018 | $57.27M | +77.8% |
| Q3 FY2018 | Sep 28, 2018 | $44.74M | +56.7% |
| Q2 FY2018 | Jun 29, 2018 | $42.49M | +50.6% |
| Q1 FY2018 | Mar 30, 2018 | $37.76M | +62.7% |
| Q4 FY2017 | Dec 29, 2017 | $32.20M | +35.3% |
| Q3 FY2017 | Sep 30, 2017 | $28.54M | – |
| Q2 FY2017 | Jun 30, 2017 | $28.21M | – |
| Q1 FY2017 | Mar 31, 2017 | $23.21M | – |
| Q4 FY2016 | Dec 31, 2016 | $23.80M | – |
See a number that looks wrong?